Loading…
Loading…
EQUITY / NASDAQ · XNCM
Citius Oncology, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.9901 USD · -1.9703%
Observed: Oct 1, 2026, 4:13 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 1.01 USD · Volume 96,706
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 3 | 2025 / Quarter 3 | Change |
|---|---|---|---|
| Revenue | 1,493,788 USD | — | — |
| Operating profit | -8,716,817 USD | -4,944,961 USD | — |
| Net income | -8,923,846 USD | -5,369,956 USD | — |
| Cash and cash equivalents | 16,563,705 USD | — | — |
| Total liabilities | 71,708,109 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 304/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 210/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 309/30/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end10/01/2024 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 304/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 16,563,705 USD | — | — | — | — | 3,924,908 USD | — | — |
| Gross profitIncome statement | 1,001,945 USD | 5,495,268 USD | — | 4,493,323 USD | — | — | — | — |
| Net incomeIncome statement | -8,923,846 USD | -41,067,610 USD | -26,609,695 USD | -32,143,764 USD | -5,534,069 USD | — | -24,761,369 USD | -5,369,956 USD |
| Operating profitIncome statement | -8,716,817 USD | -42,582,688 USD | — | -33,865,871 USD | — | — | -23,522,750 USD | -4,944,961 USD |
| RevenueIncome statement | 1,493,788 USD | 7,105,197 USD | — | 5,611,409 USD | — | — | — | — |
| Total assetsBalance sheet | 112,093,103 USD | — | — | — | — | 100,942,881 USD | 100,942,881 USD | — |
| Total equityBalance sheet | 40,384,994 USD | — | 35,268,769 USD | — | 58,413,701 USD | 44,866,231 USD | 44,866,231 USD | 32,397,913 USD |
| Total liabilitiesBalance sheet | 71,708,109 USD | — | — | — | — | 56,076,650 USD | 56,076,650 USD | — |
| Financing cash flowCash flow statement | — | 33,535,991 USD | — | 14,894,290 USD | — | — | 15,166,842 USD | — |
| Investing cash flowCash flow statement | — | -7,000,000 USD | — | -5,000,000 USD | — | — | -5,750,000 USD | — |
| Operating cash flowCash flow statement | — | -13,897,194 USD | — | -11,186,564 USD | — | — | -5,492,046 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 12/23/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.